Anti Cd 20 Ocrevus denied as not medically necessary by Cigna?

Cigna's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies Ocrelizumab on Medical-Necessity Grounds

Cigna's medical-necessity denials for ocrelizumab (Ocrevus) typically reflect a mismatch between the clinical documentation submitted and the specific criteria in Cigna's published coverage policy for anti-CD20 therapies in multiple sclerosis. Cigna reviewers look for clear chart evidence — not just a diagnosis code — that the patient's MS subtype, disease activity, and treatment history satisfy each requirement in the policy. Vague or incomplete documentation is the most common reason these denials are issued, and it is also the most correctable.

## Why This Denial Is Appealable

A medical-necessity determination is not final. Under ACA §2719 and ERISA §503, you have the right to a full-and-fair internal appeal and, if upheld, independent external review by a certified IRO. The external-review window is generally around four months from the adverse determination date; verify the exact deadline in your Cigna plan documents. Expedited review (typically 72 hours) is available when the standard timeline would seriously jeopardize health — a meaningful consideration for patients with active or progressive MS.

## Your Appeal Timeline

1. Request the denial letter and Cigna's current coverage policy for ocrelizumab — Cigna is required to provide the specific criteria used. 2. Identify the gap: compare the documentation already submitted against each listed criterion to find exactly what is missing or insufficiently documented. 3. File the internal appeal within the deadline in the denial letter (typically 180 days). 4. Submit supplemental documentation that directly addresses each unmet criterion. 5. Escalate to external review if the internal appeal is upheld.

## Documentation to Gather

• Confirmed MS diagnosis and subtype: recent neurology notes, MRI reports with radiologist interpretation, and any other diagnostic records establishing the specific form of MS.
• Disease activity and severity evidence: chart-based documentation of relapse history with dates, MRI lesion activity, and any functional or disability measures recorded in the chart — without relying on population benchmarks.
• Prior disease-modifying therapy history: names of all previously tried MS therapies, start and stop dates, documented outcomes (relapse on therapy, MRI activity, side effects), and reasons for discontinuation.
• Prescriber medical-necessity letter: a detailed letter from the treating neurologist explaining the patient's disease course, why prior therapies were insufficient or inappropriate, and why ocrelizumab is the medically necessary choice for this individual — grounded in chart facts, not population statistics.
• Applicable guideline reference: a citation to the relevant neurology guideline organization (such as the AAN) supporting ocrelizumab in the patient's clinical context.

## Criteria-Mapping Structure

Obtain Cigna's coverage policy for ocrelizumab and the FDA-approved prescribing label. Create a side-by-side table:

| Cigna / Label Requirement | Chart Evidence That Satisfies It | Source & Date | |---|---|---| | Confirmed MS subtype | Neurologist diagnosis note | [Date] | | Disease activity / severity | MRI report, relapse log | [Date] | | Prior therapy trial(s) | Treatment summary with outcomes | [Date range] | | Prescriber qualification | Board-certified neurologist | [Date] |

A criterion-by-criterion response is the most effective appeal format because it forces the reviewer to engage with the evidence for each requirement individually rather than issuing a blanket denial.